Sex-specific differences in the association of a common aldehyde dehydrogenase 2 gene polymorphism and alcohol consumption with stroke risk in a Korean population: a prospective cohort study

Chol Shin 1,2, KyuBum Kwack 2, Nam H Cho 3, Seong Hwan Kim 1, and Inkyung Baik 5 §

1Department of Internal Medicine, Korea University Ansan Hospital, Ansan 425-707, Korea  
2Institute of Human Genomic Study, Korea University Ansan Hospital, Ansan 425-707, Korea  
3Department of Biomedical Science, College of Life Science, CHA University, Seongnam 463-712, Korea  
4Department of Preventive Medicine, Ajou University School of Medicine, Suwon 443-380, Korea  
5Department of Foods and Nutrition, College of Natural Sciences, Kookmin University, 77 Jeongneung-ro Seongbuk-gu Seoul 136-702, Korea

BACKGROUND/OBJECTIVES: It is well-known that alcohol consumption is associated with stroke risk as well as with aldehyde dehydrogenase 2 gene (ALDH2) polymorphisms. However, it is unclear whether ALDH2 polymorphisms are associated with stroke risk independent of alcohol consumption and whether such association is modified by sex. We evaluated sex-specific associations of a common ALDH2 polymorphism and alcohol consumption with stroke risk in a Korean population.

SUBJECTS/METHODS: We conducted a prospective cohort study involving 8,465 men and women, aged 40-69 years and free of stroke between June, 2001 and January, 2003, and followed for the development of stroke. We identified new cases of stroke, which were self-reported or ascertained from vital registration data. Based on genome-wide association data, we selected a single-nucleotide polymorphism (rs2074356), which shows high linkage disequilibrium with the functional polymorphism of ALDH2. We conducted Cox proportional hazards regression analysis considering potential risk factors collected from a baseline questionnaire.

RESULTS: Over the median follow-up of 8 years, 121 cases of stroke were identified. Carrying the wild-type allele of the ALDH2 polymorphism increased stroke risk among men. The multivariate hazard ratio [95% confidence interval] of stroke was 2.02 [1.03-3.99] for the wild-type allele compared with the mutant alleles, but the association was attenuated after controlling for alcohol consumption. Combinations of the wild-type allele and other risk factors of stroke, such as old age, diabetes mellitus, and habitual snoring, synergistically increased the risk among men. Among women, however, the ALDH2 polymorphism was not associated with stroke risk.

CONCLUSIONS: The prospective cohort study showed a significant association between a common ALDH2 polymorphism and stroke risk in Korean men, but not in Korean women, and also demonstrated that men with genetic disadvantages gain more risk when having risk factors of stroke. Thus, these men may need to make more concerted efforts to control modifiable risk factors of stroke.

Nutrition Research and Practice 2015;9(1):79-86; doi:10.4162/nrp.2015.9.1.79; pISSN 1976-1457 eISSN 2005-6168

Keywords: ALDH2 polymorphism, alcohol consumption, stroke, prospective study

INTRODUCTION

The aldehyde dehydrogenase 2 gene (ALDH2) encodes mitochondrial aldehyde dehydrogenase (ALDH2), which detoxifies acetaldehyde generated from the oxidation of ethanol by alcohol dehydrogenase. A common functional polymorphism, ALDH2 Glu504Lys, has been identified; its allelic variants are known to be responsible for different enzyme activities, which affect the clearance rate of ethanol [1]. The ALDH2 polymorphism is reportedly associated with alcohol consumption [2,3], cancer [4,5], hypertension [6,7], diabetes mellitus [8], and coronary artery disease (CAD) [9-11] primarily among Asian populations. Alcohol consumption is thought to underlie the association between the ALDH2 polymorphism and these diseases, but the direct role of the ALDH2 polymorphism in pathological mechanisms of disease cannot be ruled out [12]. Particularly, individuals with the ALDH2 mutant allele with null or low enzyme activity are more likely to have CAD [9-11].
Findings regarding the association between ALDH2 variants and hypertension are inconsistent. A case-control study reported that individuals with the wild-type allele are more likely to have hypertension [6] whereas a prospective study showed that those possessing the mutant allele in ALDH2 are at an increased risk of hypertension [7]. No data have been reported regarding the association between the ALDH2 polymorphism and stroke. A previous study identified a significant association between a common ALDH2 polymorphism and high alcohol consumption among patients with stroke, but was unable to investigate on association with stroke risk itself [13]. In a meta-analysis of accumulating data, a J-shaped relationship between alcohol consumption and stroke risk was observed; alcohol consumption less than 12 g/day was optimal for preventing stroke in prospective cohort studies whereas 15 to 30 g/day was shown as optimal consumption in case-control studies [14]. This discrepancy may be due to response errors in self-reported alcohol consumption, a lack of consideration of binge drinking behavior, or genetic variation, particularly allelic variation at alcohol metabolism genes.

Recently, we discovered common ALDH2 polymorphisms highly associated with alcohol consumption as well as with alcoholism, such as rs2074356 and rs11066280, which are considered to reflect rs671, non-synonymous SNPs of ALDH2 [3]. In particular, rs2074356 was discovered as a SNP associated with coronary artery disease risk [15]. In present study, we considered this SNP a surrogate of functional polymorphism of ALDH2 and used to estimate stroke risk in a prospective cohort study. In analysis of 8-year follow-up data, we considered a number of potential risk factors including the presence of metabolic diseases, lifestyle factors, and daily amounts of alcohol consumed to identify the role of the ALDH2 polymorphism in developing stroke. Furthermore, we evaluated the joint effects of genetic factors and other risk factors on stroke risk.

**SUBJECTS AND METHODS**

**Study population**

Study participants were from population-based cohorts embedded in the Korean Genome Epidemiology Study (KGES), which is an ongoing longitudinal investigation. Cohort members included Korean men (n = 4,752) and women (n = 5,261), aged 40-69 years and residing in 2 cities, Ansan and Ansung, when they were enrolled between June, 2001 and January, 2003. Detailed information regarding enrollment of cohort members and study procedures is available in a previous report [3]. Briefly, cohort members were recruited based on a two-stage cluster sampling procedure and were enrolled after undergoing a comprehensive health examination and on-site interviews, which were administered by trained personnel. At the health examination, cohort members provided blood specimens for evaluation of biochemical parameters to measure lipid and glucose metabolism as well as for genetic assays. They completed questionnaire-based interviews to collect data on socio-demographics, medical history and health conditions, family history of disease, and lifestyle factors. They have also been followed biennially and have undergone similar health examination and interviews. At each visit, the participants sign an informed consent form, which was approved by the Human Subjects Review Committee either at the Ajou University Medical Center or at the Korea University Ansan Hospital. All procedures and protocols of the study were approved by both institutions.

Among a total of 8,716 individuals whose clinical and genetic data were available at baseline, we excluded 10 persons who reported pregnancy at baseline (n = 1), who did not complete the baseline anthropometric measurement (n = 3), or who did not provide information on alcohol consumption (n = 6). Because the outcomes of this study are new cases of stroke, we excluded 89 persons who reported at baseline a physician-diagnosis of stroke. Additionally, we further excluded 152 persons who reported at baseline a physician-diagnosis of coronary artery disease, congestive heart failure, or peripheral artery disease to minimize the effects of these diseases. After exclusions, a total of 8,465 participants (47% men and 53% women) were entered for analysis.

**Outcome**

The outcomes of this study were incident events or deaths due to stroke during a follow-up period from April, 2003 to December, 2010. Incident events were self-reported by interview-based questionnaires and deaths were ascertained with its cause and date based on vital registration data, which are periodically compiled by the Korea National Statistical Office. We excluded 10 persons who reported a diagnosis of both CAD and stroke during follow-up to distinguish risk factors of stroke from those of CAD. Concordance between self-reported diagnoses of stroke and those ascertained by brain magnetic resonance imaging was 91% in a subgroup of stroke cases.

**Common ALDH2 gene polymorphism**

To examine the ALDH2 polymorphism, we focused on the most significant single-nucleotide polymorphism (SNP), rs2074356, which was reported to be highly associated with alcohol consumption (adjusted P-value < 9.5 × 10^{-5}) and to be a surrogate marker of ALDH2 Glu504Lys (rs671) in previous genome-wide association (GWA) studies [3,15]. Genotypes of this SNP were observed to be CC, CT, and TT; its minor allele (T) frequency was 0.15 among male drinkers [3]. An earlier report provided information regarding the preparation of genomic samples, genotyping method, and quality control for the GWA data [16].

**Potential risk factors**

We collected information on age, sex, family history of stroke, smoking status, snoring during sleep, physical activity, alcohol drinking status, and amount of alcohol consumed from questionnaires used at the initial interview. Participants were asked whether their biological parents and sibling had been diagnosed with stroke. Regarding snoring status, they were asked if they snore; if so, they were further asked how frequently they snore (infrequently, 1 to 3 times per week, 4 to 5 times per week, 6 to 7 times per week). To collect information regarding daily physical activity, participants were asked to report hours spent in a typical day in sleep and 5 categories
of activity intensity (sedentary, very light, light, moderate, vigorous), given details on activities corresponding to each category. Specific metabolic equivalent (MET) values assigned to each category were multiplied by the reported hours spent to yield a total metabolic equivalent (MET-hours) score as a quantitative estimate of physical activity. Participants were asked whether they had ever consumed alcoholic beverages in their lifetime, whether there was a time in their life when they regularly consumed at least one drink of any alcoholic beverage in every month, and whether they drank in the past 30 days. They were also requested to complete a table to collect information on the average frequency of drinking and amount of alcoholic beverages consumed during a typical occasion in the past 30 days. Such information was used to calculate daily alcohol consumption (g/day).

At the health examination, height (cm) and body weight (kg) were measured by health professionals trained with a standardized protocol to yield body mass index (BMI, kg/m²). Based on biochemical and clinical evaluations and self-reports on medications, the presence of hypertension (systolic/diastolic pressure \( \geq 140/90 \) mmHg), diabetes mellitus (fasting glucose \( \geq 126 \) mg/dL or 2-hour glucose \( \geq 200 \) mg/dL), or hypercholesterolemia (serum total cholesterol \( \geq 240 \) mg/dL) was determined.

Statistical analysis

Descriptive statistics on baseline characteristics of the study population were calculated. To analyze the association between stroke risk and ALDH2 polymorphic variants and potential risk factors, we conducted Cox proportional hazards regression analysis. The person-years for each subject were calculated from the date when he or she participated in the baseline examination to the date when he or she reported the first stroke events in follow-up examinations or to death date or to December 31, 2010, whichever came first. Persons who died, refused further participation, or were lost to follow-up were censored. The length of follow-up period used for analysis was 9.5 years with a median follow-up period of 7.8 years. Stroke risk was expressed as a hazard ratio (HR) with its 95% confidence interval (CI). In multivariate models, age, BMI, and physical activity were adjusted as a continuous variable and other variables were treated as categorical variables, including current smoking status (nonsmoking, moderate smoking of 20 cigarettes per day or fewer, heavy smoking of 21 cigarettes per day or more), snoring status (no snoring, snoring for 1-3 nights per week, snoring for 4-6 nights per week or every night), and current alcohol drinking status (nondrinking in the past 30 days, light alcohol drinking of 1 drink per day or fewer, moderate alcohol drinking of 2 drinks per day, heavy alcohol drinking of 3 drinks per day or more). However, because the proportion of heavy smokers or heavy drinkers was trivial in women, categories for smokers and drinkers were united. ALDH2 polymorphic variants (mutant type and wild-type), the presence of family history of stroke, and the presence of hypertension, diabetes mellitus, and hypercholesterolemia were fitted as binary variables in the model. Two multivariate Cox models stratified by sex were fitted as binary variables in the model. Two multivariate Cox models stratified by sex were also performed. Joint effects of ALDH2 variants and significant risk factors of stroke were analyzed after taking other covariates into account. Proportional hazards assumptions were tested for the second model and no violation was confirmed. All testing was based on a two-sided level of significance. The SAS program (SAS 9.1.3, 2008, SAS Institute, Cary, NC, USA) was used to conduct statistical analyses.

RESULTS

Baseline characteristics

Over median follow-up of 7.8 years, 121 cases (67 men and 54 women) of stroke (99 incident events and 22 deaths due to stroke) were newly identified, with 53035.5 person-years accrued for analysis. A comparison of cohort members who were followed up until 2010 or ascertained as stroke cases with those lost during the follow-up period revealed no significant difference in the distribution of the wild-type (CC) and the mutant type (CT or TT) of the ALDH2 polymorphism (rs2074356) \((P = 0.66)\).

Characteristics of the study population according to ALDH2 polymorphic variants are presented in Table 1. Of these, 27% had the mutant allele. Persons with the wild-type allele were more likely to suffer from hypertension or diabetes mellitus described above and current alcohol status. Analyses stratified according to alcohol drinking status were also performed. Joint effects of ALDH2 variants and significant risk factors of stroke were analyzed after taking other covariates into account. Proportional hazards assumptions were tested for the second model and no violation was confirmed. All testing was based on a two-sided level of significance. The SAS program (SAS 9.1.3, 2008, SAS Institute, Cary, NC, USA) was used to conduct statistical analyses.

Table 1. Baseline characteristics of the study population (n = 8,465) according to the aldehyde dehydrogenase gene (ALDH2) polymorphism

| Characteristics                          | Wild-type | Mutant type | P-value |
|------------------------------------------|-----------|-------------|---------|
| Number of subjects                       | 6172      | 2293        |         |
| Stroke cases, %                          | 1.5       | 1.2         | 0.23    |
| Age, yrs                                 | 52.1 ± 8.8| 52.3 ± 9.0  | 0.32    |
| Male, %                                  | 47.7      | 46.7        | 0.42    |
| Family history of stroke, %              | 9.8       | 10.4        | 0.42    |
| Presence of diseases, %                  |           |             |         |
| Hypertension                             | 31.3      | 26.7        | < 0.001 |
| Diabetes mellitus                        | 13.7      | 11.3        | < 0.01  |
| Hypercholesterolemia                     | 13.4      | 13.9        | 0.57    |
| Body mass index, kg/m²                   | 24.6 ± 3.1| 24.5 ± 3.1  | < 0.05  |
| Smoking status, %                        |           |             | 0.88    |
| Nonsmoking                               | 73        | 73.4        |         |
| Smoking ≤ 20 cigarettes/day              | 23.2      | 22.7        |         |
| Smoking > 20 cigarettes/day              | 3.8       | 3.9         |         |
| Snoring during sleep, %                  |           |             | 0.29    |
| Non-snoring                              | 36.3      | 37.7        |         |
| Snoring 1-3 nights/week                  | 49.6      | 47.7        |         |
| Snoring ≥ 4 nights/week                  | 14.1      | 14.7        |         |
| Physical activity\(^2\)                  | 30.9 ± 15.4| 30.8 ± 15.4| 0.95    |
| Alcohol consumption, %                   |           |             | < 0.001 |
| Nondrinking                              | 43.7      | 73.6        |         |
| 1 drink/day                              | 32.8      | 21.1        |         |
| ≥ 2 drinks/day                           | 9.7       | 2.7         |         |
| ≥ 3 drinks/day                           | 13.9      | 2.7         |         |

Data are mean ± SD for continuous variables;
\(^2\)Average daily metabolic equivalents-hours (MET-hours)
Table 2. Hazard ratios (HR) and 95% confidence interval (CI) of stroke incidence among men (n = 4,011)

| Potential risk factors         | Categories       | No of cases / non-cases | Unadjusted HR (95% CI) | Model 1 HR (95% CI) | Model 2 HR (95% CI) |
|--------------------------------|------------------|-------------------------|------------------------|---------------------|---------------------|
| ALDH2 variants                 | Mutant type      | 10/1,060                | reference              | reference           | reference           |
|                                | Wild-type        | 57/2,884                | 2.07 (1.06, 4.05)      | 2.02 (1.03, 3.99)   | 1.99 (0.96, 4.13)   |
| Age, yrs                       |                  | 67/3,944                | 1.09 (1.06, 1.12)      | 1.10 (1.07, 1.14)   | 1.10 (1.07, 1.14)   |
| Family history of stroke       | Absence          | 58/3,531                | reference              | reference           | reference           |
|                                | Presence         | 9/413                   | 1.26 (0.62, 2.54)      | 1.29 (0.63, 2.64)   | 1.30 (0.63, 2.65)   |
| Hypertension                   | Absence          | 36/2,738                | reference              | Reference           | reference           |
|                                | Presence         | 31/1,206                | 2.03 (1.26, 3.28)      | 1.37 (0.83, 2.26)   | 1.36 (0.82, 2.25)   |
| Diabetes mellitus              | Absence          | 46/3,402                | reference              | reference           | reference           |
|                                | Presence         | 21/542                  | 2.85 (1.70, 4.78)      | 1.93 (1.13, 3.29)   | 1.85 (1.08, 3.17)   |
| Hypercholesterolemia           | Absence          | 57/3,420                | reference              | reference           | reference           |
|                                | Presence         | 10/524                  | 1.17 (0.60, 2.28)      | 1.20 (0.60, 2.37)   | 1.18 (0.60, 2.35)   |
| Body mass index, kg/m²         |                  | 67/3,944                | 1.02 (0.94, 1.11)      | 1.02 (0.93, 1.11)   | 1.02 (0.93, 1.11)   |
| Smoking status                 | Nonsmoking       | 34/1,968                | reference              | reference           | reference           |
|                                | ≤ 20 cigarettes/day | 26/1,661              | 0.96 (0.58, 1.60)      | 1.14 (0.67, 1.91)   | 1.11 (0.65, 1.89)   |
|                                | > 20 cigarettes/day | 7/315                 | 1.35 (0.60, 3.04)      | 1.91 (0.84, 4.38)   | 1.83 (0.79, 4.24)   |
| Snoring during sleep, %        | No               | 14/1,253                | reference              | reference           | reference           |
|                                | 1-3 nights/week  | 33/2,006                | 1.47 (0.79, 2.74)      | 1.75 (0.92, 3.32)   | 1.77 (0.93, 3.35)   |
|                                | ≥ 4 nights/week  | 20/685                  | 2.50 (1.27, 4.96)      | 3.00 (1.47, 6.15)   | 2.89 (1.41, 5.92)   |
| Physical activity, MET-hours   |                  | 67/3,944                | 1.00 (0.99, 1.02)      | 1.00 (0.98, 1.01)   | 1.00 (0.98, 1.01)   |
| Alcohol drinking status        | Nondrinking      | 18/1,101                | 1.51 (0.76, 3.00)      | -                   | 1.64 (0.80, 3.34)   |
|                                | 1 drink/day      | 15/1,384                | reference              | -                   | reference           |
|                                | 2 drinks/day     | 15/592                  | 2.09 (1.02, 4.27)      | -                   | 1.96 (0.95, 4.04)   |
|                                | ≥ 3 drinks/day   | 19/867                  | 2.05 (1.04, 4.03)      | -                   | 1.84 (0.92, 3.66)   |

Model 1: Data are adjusted for all potential risk factors, except alcohol drinking status, listed in the table.
Model 2: Data are further adjusted for alcohol drinking status with covariates in Model 1.

Table 3. Hazard ratios (HR) and 95% confidence interval (CI) of stroke incidence among women (n = 4,454)

| Potential risk factors         | Categories       | No of cases / non-cases | Unadjusted HR (95% CI) | Model 1 HR (95% CI) | Model 2 HR (95% CI) |
|--------------------------------|------------------|-------------------------|------------------------|---------------------|---------------------|
| ALDH2 variants                 | Mutant type      | 17/1,206                | reference              | reference           | reference           |
|                                | Wild-type        | 37/3,194                | 0.81 (0.45, 1.43)      | 0.83 (0.47, 1.48)   | 0.77 (0.42, 1.40)   |
| Age, yrs                       |                  | 54/4,400                | 1.08 (1.05, 1.12)      | 1.08 (1.04, 1.12)   | 1.08 (1.05, 1.12)   |
| Family history of stroke       | Absence          | 47/3,983                | reference              | reference           | reference           |
|                                | Presence         | 7/417                   | 1.36 (0.62, 3.01)      | 1.33 (0.60, 2.96)   | 1.32 (0.59, 2.94)   |
| Hypertension                   | Absence          | 33/3,114                | reference              | reference           | reference           |
|                                | Presence         | 21/1,286                | 1.60 (0.93, 2.76)      | 1.02 (0.57, 1.83)   | 1.01 (0.56, 1.82)   |
| Diabetes mellitus              | Absence          | 46/3,870                | reference              | reference           | reference           |
|                                | Presence         | 8/530                   | 1.36 (0.64, 2.88)      | 0.94 (0.44, 2.04)   | 0.95 (0.44, 2.06)   |
| Hypercholesterolemia           | Absence          | 44/3,796                | reference              | reference           | reference           |
|                                | Presence         | 10/604                  | 1.49 (0.75, 2.97)      | 1.16 (0.57, 2.34)   | 1.15 (0.57, 2.33)   |
| Body mass index, kg/m²         |                  | 54/4,400                | 0.99 (0.91, 1.07)      | 0.95 (0.87, 1.04)   | 0.95 (0.87, 1.04)   |
| Smoking status                 | Nonsmokers       | 51/4,134                | reference              | reference           | reference           |
|                                | Smokers          | 3/266                   | 1.05 (0.33, 3.38)      | 0.93 (0.29, 2.98)   | 0.84 (0.26, 2.75)   |
| Snoring during sleep, %        | No               | 14/1,825                | reference              | reference           | reference           |
|                                | 1-3 nights/week  | 28/2,087                | 1.71 (0.90, 3.26)      | 1.65 (0.86, 3.16)   | 1.65 (0.86, 3.17)   |
|                                | ≥ 4 nights/week  | 12/488                  | 3.19 (1.48, 6.91)      | 2.58 (1.16, 5.77)   | 2.56 (1.15, 5.73)   |
| Physical activity, MET-hours   |                  | 54/4,400                | 1.00 (0.98, 1.01)      | 0.99 (0.97, 1.01)   | 0.99 (0.97, 1.01)   |
| Alcohol drinking status        | Nondrinkers      | 40/3,223                | 1.11 (0.59, 2.07)      | -                   | 0.75 (0.38, 1.47)   |
|                                | 1 drink/day      | 13/1,093                | reference              | -                   | reference           |
|                                | ≥ 2 drinks/day   | 1/84                    | 1.23 (0.16, 9.44)      | -                   | 1.47 (0.19, 11.35)   |

Model 1: Data are adjusted for all potential risk factors, except alcohol drinking status, listed in the table.
Model 2: Data are further adjusted for alcohol drinking status with covariates in Model 1.
(P < 0.01), have a greater BMI (P < 0.05), and consume more alcoholic beverages (P < 0.001) compared with those with the mutant alleles.

**Associations between stroke risk and the ALDH2 Polymorphism and other risk factors by sex**

Table 2 shows the association between stroke risk and ALDH2 variants and potential risk factors among 4,011 men. Men with the wild-type of the ALDH2 polymorphism showed an increased risk of stroke. Compared with the mutant alleles of the ALDH2 polymorphism, the multivariate HR [95% CI] of stroke was 2.02 [1.03-3.99] for those with the wild-type before adjusting for alcohol consumption; values were not significant after adjustment. However, alcohol consumption itself was not significantly associated with stroke risk according to the multivariate model. The lowest risk of stroke was observed in light alcohol drinkers who consumed an average of 1 drink (15 g of alcohol) per day. In the second model that was further adjusted for alcohol consumption, aging, the presence of diabetes mellitus, and habitual snoring were observed to be significant risk factors of stroke. Men with diabetes mellitus had a 1.9-fold higher risk than those without. In addition, men who snored 4-7 nights per week had a 3-fold higher risk than non-snorers (Table 2). After adjusting for alcohol consumption, the previous results, except those for the ALDH2 polymorphism, were not changed (Table 2).

Table 3 shows the association between stroke risk and ALDH2 variants and potential risk factors for 4,454 women. The ALDH2 polymorphism was not associated with the stroke risk, regardless of adjusting for alcohol consumption. In the second multivariate model that was further adjusted for alcohol consumption, aging and habitual snoring were observed to be significant risk factors of stroke. Women who snored 4-7 nights per week had a 2.6-fold higher risk of stroke than non-snorers (Table 3).

**Associations between stroke risk and the ALDH2 polymorphism and other risk factors by Alcohol drinking status**

Multivariate results stratified by current status of alcohol drinking among men or women are presented in Table 4. Aging was found to be a significant risk factor, regardless of sex and alcohol drinking status. Although the association was not significant, carrying the wild-type of the ALDH2 polymorphism generally increased the risk of stroke in male non-drinkers or drinkers, but generally decreased the risk in women. The presence of diabetes mellitus or snoring significantly increased the risk of stroke in male drinkers. Among women, the presence of snoring tended to increase the risk, but the association was not significant for either non-drinkers or drinkers.

**Joint effects of the ALDH2 polymorphism and risk factors on stroke risk**

Table 5 shows the joint effects of the ALDH2 polymorphism and other significant risk factors such as aging, presence of diabetes mellitus, and snoring on stroke risk after taking into account other potential risk factors. Among men, the multivariate HR [95% CI] of stroke risk was 6.88 [2.78-17.05] for carriers of the wild-type aged 60 years or older compared with those with the mutant alleles aged 59 years or younger. Carriers of the wild-type allele with diabetes mellitus had a 3.6-fold [1.62-8.03] increased risk of stroke compared with those with the mutant alleles without diabetes mellitus, while snorers with the wild-type had an 8.5-fold [1.16-61.74] increased risk compared with non-snorers with the mutant alleles among men. However, joining of the ALDH2 polymorphism and snoring status was not significantly associated with stroke risk among

---

**Table 4. Multivariate hazard ratios (HR) and 95% confidence interval (CI) of stroke incidence according to alcohol drinking status**

| Potential risk factors | Categories                  | Male nondrinkers (n = 1,119) | Male drinkers (n = 2,892) | Female nondrinkers (n = 3,263) | Female drinkers (n = 1,191) |
|------------------------|-----------------------------|------------------------------|---------------------------|-------------------------------|----------------------------|
|                        |                             | HR (95% CI)                  | HR (95% CI)               | HR (95% CI)                   | HR (95% CI)                |
| ALDH2 variants         | Mutant type                 | reference                    | reference                 | reference                     | reference                 |
|                        | Wild-type                   | 2.26 (0.81, 6.25)            | 2.08 (0.74, 5.81)         | 0.83 (0.44, 1.58)             | 0.49 (0.11, 2.29)          |
| Age, yrs               |                             | 1.09 (1.02, 1.15)            | 1.10 (1.06, 1.14)         | 1.09 (1.04, 1.13)             | 1.07 (1.00, 1.15)          |
| Family history of stroke | Absence                    | reference                    | reference                 | reference                     | reference                 |
|                        | Presence                    | 2.27 (0.73, 7.06)            | 0.96 (0.37, 2.48)         | 1.57 (0.67, 3.76)             | 0.69 (0.09, 5.38)          |
| Hypertension           | Absence                    | reference                    | reference                 | reference                     | reference                 |
|                        | Presence                    | 2.36 (0.89, 6.23)            | 1.17 (0.65, 2.11)         | 0.98 (0.50, 1.93)             | 1.23 (0.38, 3.99)          |
| Diabetes mellitus      | Absence                    | reference                    | reference                 | reference                     | reference                 |
|                        | Presence                    | 1.55 (0.54, 4.50)            | 2.11 (1.14, 3.92)         | 0.85 (0.35, 2.07)             | 1.33 (0.28, 6.19)          |
| Hypercholesterolemia   | Absence                    | reference                    | reference                 | reference                     | reference                 |
|                        | Presence                    | 0.85 (0.19, 3.81)            | 1.38 (0.64, 3.02)         | 1.04 (0.45, 2.40)             | 1.69 (0.45, 6.34)          |
| Body mass index, kg/m² |                             | 0.98 (0.63, 1.55)            | 1.03 (0.93, 1.14)         | 0.97 (0.87, 1.07)             | 0.93 (0.78, 1.11)          |
| Smoking status         | Nonsmokers                  | reference                    | reference                 | reference                     | reference                 |
|                        | Smokers                     | 1.46 (0.51, 4.12)            | 1.29 (0.72, 2.30)         | 1.23 (0.29, 5.21)             | 0.51 (0.07, 4.06)          |
| Snoring during sleep, %| No                          | reference                    | reference                 | reference                     | reference                 |
|                        | 1-3 nights/week             | 2.20 (0.59, 8.16)            | 1.61 (0.77, 3.37)         | 1.70 (0.79, 3.67)             | 1.45 (0.41, 5.10)          |
|                        | 4 nights/week               | 3.31 (0.75, 14.55)           | 2.86 (1.25, 6.52)         | 2.55 (0.99, 6.51)             | 2.46 (0.51, 11.97)         |
| Physical activity, MET-hours |                     | 0.96 (0.93, 1.00)            | 1.00 (0.99, 1.02)         | 0.98 (0.96, 1.00)             | 1.02 (0.99, 1.05)          |

Data are adjusted for all potential risk factors listed in the table,
Table 5. Multivariate hazard ratios (HR) and 95% confidence interval (CI) for joint effects of the ALDH2 polymorphism and other risk factors on stroke incidence

| Risk factors                  | ALDH2 variants | Unadjusted HR (95% CI) | Multivariate HR (95% CI) |
|------------------------------|----------------|------------------------|-------------------------|
| **Among men**                |                |                        |                         |
| Age                          |                |                        |                         |
| < 60 yrs                     | Mutant type    | reference              | reference               |
| ≥ 60 yrs                     | Mutant type    | 1.97 (0.56, 6.99)      | 2.27 (0.63, 8.19)       |
| < 60 yrs                     | Wild-type      | 1.50 (0.62, 3.65)      | 1.43 (0.59, 3.48)       |
| ≥ 60 yrs                     | Wild-type      | 6.41 (2.67, 15.36)     | 6.88 (2.78, 17.05)      |
| Diabetes mellitus            |                |                        |                         |
| Absence                      | Mutant type    | reference              | reference               |
| Presence                     | Mutant type    | 1.03 (0.13, 8.13)      | 0.87 (0.11, 6.97)       |
| Absence                      | Wild-type      | 1.59 (0.77, 3.29)      | 1.75 (0.84, 3.65)       |
| Presence                     | Wild-type      | 4.76 (2.17, 10.46)     | 3.61 (1.62, 8.03)       |
| Snoring status               |                |                        |                         |
| Non-snoring                  | Mutant type    | reference              | reference               |
| Snoring                      | Mutant type    | 4.24 (0.54, 33.47)     | 5.07 (0.64, 40.16)      |
| Non-snoring                  | Wild-type      | 4.82 (0.63, 36.87)     | 4.73 (0.62, 36.27)      |
| Snoring                      | Wild-type      | 7.43 (1.02, 58.90)     | 8.45 (1.16, 61.74)      |
| **Among women**              |                |                        |                         |
| Age                          |                |                        |                         |
| < 60 yrs                     | Mutant type    | reference              | reference               |
| ≥ 60 yrs                     | Mutant type    | 2.38 (0.92, 6.16)      | 2.11 (0.79, 5.63)       |
| < 60 yrs                     | Wild-type      | 0.73 (0.33, 1.63)      | 0.73 (0.33, 1.63)       |
| ≥ 60 yrs                     | Wild-type      | 2.14 (0.97, 4.73)      | 1.98 (0.87, 4.51)       |
| Snoring status               |                |                        |                         |
| Non-snoring                  | Mutant type    | reference              | reference               |
| Snoring                      | Mutant type    | 1.75 (0.62, 4.97)      | 1.51 (0.53, 4.33)       |
| Non-snoring                  | Wild-type      | 0.69 (0.23, 2.06)      | 0.67 (0.22, 2.01)       |
| Snoring                      | Wild-type      | 1.47 (0.57, 3.82)      | 1.30 (0.49, 3.41)       |

Data are adjusted for all potential risk factors listed in the Table 4.

**DISCUSSION**

In this prospective cohort study, we found that carrying the wild-type ALDH2 polymorphism is a risk factor of stroke in men. After taking into account age, family history of stroke, presence of hypertension, diabetes mellitus, and hypercholesterolemia, BMI, smoking status, snoring status, and physical activity as potential risk factors of stroke, men carrying the wild-type of the ALDH2 polymorphism had a 2-fold higher risk of developing stroke compared with carriers of the mutant alleles. However, this association was attenuated after further adjusting for alcohol consumption. Stroke risk associated with the wild-type allele generally increased in both non-drinkers and drinkers with recent alcohol consumption. Thus, alcohol consumption may mediate this association and the ALDH2 polymorphism may reflect not only recent alcohol consumption but also alcohol drinking behavior in the remote past. Among women, no association between the ALDH2 polymorphism and stroke risk was observed.

It is well-known that alcohol drinking behavior is associated with the ALDH2 polymorphism among Asian populations [1,3] and with the alcohol dehydrogenase gene (ADH) polymorphism among non-Asian populations [17]. The ALDH2 *S04Lys variant is present in up to 41% of Asians, 0 to 2.5% of Africans, and 0 to 1.5% of other ethnicities [18]. Carriers of the heterozygous variant allele have low ALDH2 enzyme activity and those with the homozygous allele have null activity [1]. Thus, these carriers have no or a low capacity to eliminate toxic acetaldehyde and are likely to show aversive physiological responses such as facial flushing, hypotension, palpitations, tachycardia, and vomiting even with small amounts of alcohol consumed [1,19]. Such unpleasant reactions are advantageous in terms of alcohol drinking behavior because carriers of the ALDH2 *S04Lys variant generally drink less alcohol or are less likely to become alcoholic [19]. However, some studies reported disadvantageous influences of the ALDH2 *S04Lys variant on CAD [9-11].

To the best of our knowledge, the present investigation is a sole epidemiological study involving a large sample to evaluate the association between the ALDH2 *S04Lys variant and stroke risk. A cross-sectional study first examined brain magnetic resonance imaging in 376 men and women and found that men without the ALDH2 *S04Lys variant are more likely to have multiple lacunar infarcts [20]. No studies have reported the association between ALDH2 polymorphisms and stroke, whereas some studies have investigated the association between ADH polymorphisms and stroke [21,22]. In our study, analysis stratified by sex showed that the risk of stroke was significantly associated with the wild-type ALDH2 polymorphism in men, but not in women. This finding may be due in part to the social climate to tolerate heavy alcohol drinking for men, but not for women (particularly for house-wives), in Korea. Additionally, we speculate for men that the ALDH2 polymorphism reflects alcohol consumption, not only in the past 30 days but also in the remote past, in its association with stroke. Because men carrying the wild-type polymorphism are expected to have biological tolerance towards heavy alcohol drinking, even those who did not drink alcohol recently or regularly may have drunk alcohol occasionally under the social climate to promote alcohol drinking. Thus, the increased stroke risk associated with the ALDH2 polymorphism among male non-drinkers may be related to occasional binge drinkers in non-drinkers. A joint analysis of the presence of diabetes mellitus or snoring with carrying the wild-type allele showed additive effects on stroke risk. Some data support that alcohol drinking aggravates snoring [23], which was unclear in our data. Interestingly, the magnitude of the association between snoring and stroke risk appeared to be greater in this study than in other studies [24-26]. Other risk factors of stroke such as family history of stroke and hypercholesterolemia were not associated with stroke even in the univariate analysis and these results may be partly due to small numbers of cases.

Our findings support an association between alcohol drinking and stroke [14], although the independent effects of the ALDH2 polymorphism on stroke cannot be ruled out. Previous studies showed a role for ALDH2 enzyme activity in protecting heart against ischemic damages [27] and in bioactivation of nitroglycerin, which is widely used to treat patients with heart disease [28]. However, these data imply disadvantageous effects of null or low activity of ALDH2 enzyme, which is a phenotype for carriers of the ALDH2 *S04Lys variant. Thus, it is unclear whether carrying the ALDH2 *S04Lys variant is protective against stroke independent of alcohol drinking. The biological mechanisms...
underlying the association between heavy alcohol consumption and stroke includes alcohol-induced hypertension, cardiac arrhythmias, blood clotting, and reduction of cerebral blood flow [29].

Strengths of our study include its population-based design, the large sample analyzed with genetic data, prospective follow-up of stroke cases, and inclusion of a broad range of confounding factors. In the interpretation of our findings, however, some limitations should be noted. In our study, most events of stroke were documented based on questionnaire data since pathological information was unavailable, although we confirmed some cases through medical records. Vital registration data from some cases through medical records. Vital registration data from the registration system requires a medical certificate of death. Therefore, misclassification of incident events may have occurred. Particularly, the incidence of stroke may be underestimated because of unreported cases, healthy cohorts, or persons lost during follow-up. The prevalence of self-reported stroke among Korean adults between 40 and 69 years from national survey data is approximately 1.5%, while it was 1% in previous reports [3,15]. Although rs2074356 is an inborn SNP, its contribution to the development of stroke independent of ALDH2 Glu504Lys cannot be ruled out. It is an emerging research field to identify the role of inborn SNPs in gene expression. Finally, it is difficult to generalize our results, and thus further investigations are necessary to analyze other ethnic groups.

In summary, this prospective cohort study showed that men carrying the wild-type ALDH2 polymorphism had a 2-fold higher risk of developing stroke compared with carriers of the mutant allele after taking into account a broad range of confounding factors. Among women, no association between the ALDH2 polymorphism and stroke risk was observed. Given the hypothesis that alcohol consumption mediates the association between the ALDH2 polymorphism and stroke risk, heavy alcohol consumption should be avoided for high-risk populations with genetic predisposition to stroke.

REFERENCES

1. Thomasson HR, Crabb DW, Edenberg HJ, Li TK. Alcohol and aldehyde dehydrogenase polymorphisms and alcoholism. Behav Genet 1993;23:131-6.
2. Takeuchi F, Isono M, Nabika T, Katsuya T, Sugiyama T, Yamaguchi S, Kobayashi S, Ogihara T, Yamori Y, Fujioka A, Kato N. Confirmation of ALDH2 as a Major locus of drinking behavior and of its variants regulating multiple metabolic phenotypes in a Japanese population. Circ J 2011;75:911-8.
3. Baik I, Cho NH, Kim SH, Han BG, Shin C. Genome-wide association studies identify genetic loci related to alcohol consumption in Korean men. Am J Clin Nutr 2011;93:809-16.
4. Yang SJ, Yokoyama A, Yokoyama T, Huang YC, Wu SY, Shao Y, Niu J, Wang J, Liu Y, Zhou XQ, Yang CX. Relationship between genetic polymorphisms of ALDH2 and ADH1B and esophageal cancer risk: a meta-analysis. World J Gastroenterol 2010;16:4210-20.
5. Duell EJ, Sala N, Travier N, Muñoz X, Boutron-Ruault MC, Clavel-Chapelon F, Barricarte A, Arriola L, Navarro C, Sánchez-Cantalejo E, Quíroz JR, Krogh V, Vineis P, Mattiello A, Tumino R, Khaw KT, Wareham N, Allen NE, Peeters PH, Nuñez ME, Bueno-de-Mesquita HB, van Oijen MG, Bammia C, Benetou V, Trichopoulos D, Canzian F, Kaaks R, Boeing H, Bergmann MM, Lund E, Ehmström R, Johansen D, Hallmans G, Sterling R, Tjønneland A, Overvad K, Ostergaard JN, Ferrari P, Fedirko V, Jenab M, Nesi G, Riboli E, González CA. Genetic variation in alcohol dehydrogenase (ADH1A, ADH1B, ADH1C, ADH7) and aldehyde dehydrogenase (ALDH2), alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Carcinogenesis 2012;33:361-7.
6. Hiura Y, Tabara Y, Kokubo Y, Okamura T, Miki T, Tomoike H, Iwai N. A genome-wide association study of hypertension-related phenotypes in a Japanese population. Circ J 2010;74:2353-9.
7. Chang YC, Chiu YF, Lee IT, Ho LT, Hung YJ, Hsiung CA, Quentermou T, Donlon T, Lee WJ, Lee PC, Chen CH, Mochly-Rosen D, Chuang LM. Common ALDH2 genetic variants predict development of hypertension in the SAPPHiRe prospective cohort: gene-environmental interaction with alcohol consumption. BMC Cardiovasc Disord 2012;12:58.
8. Suzuki Y, Muramatsu T, Taniyama M, Atsumi Y, Kawaguchi R, Higuchi S, Hosokawa K, Ashahina T, Murata C, Matsuoka K. Association of aldehyde dehydrogenase with inheritance of NIDDM. Diabetologia 1996;39:1115-8.
9. Takagi S, Iwai N, Yamauuchi K, Kojima S, Yasuno S, Baba T, Terashima M, Tsutsumi Y, Suzuki S, Morii I, Hanai S, Ono K, Baba S, Tomoike H, Kawamura A, Miyazaki S, Nonogi H, Goto Y. Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men. Hypertens Res 2002;25:677-81.
10. Jo SA, Kim EK, Park MH, Han C, Park HY, Jang Y, Song BJ, Jo I. A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men. Clin Chim Acta 2007;382:42-7.
11. Guo YJ, Chen L, Bai YP, Li L, Sun J, Zhang GG, Yang TL, Xia J, Li YJ, Chen XP. The ALDH2 Glu504Lys polymorphism is associated with coronary artery disease in Han Chinese: Relation with endothelial ADMA levels, Atherosclerosis 2010;211:545-50.
12. Chen CH, Sun L, Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res 2010;88:51-7.
13. Yao CT, Cheng CA, Wang HK, Chiu SW, Chen YC, Wang MF, Yin SJ, Peng GS. The role of ALDH2 and ADH1B polymorphism in alcohol consumption and stroke in Han Chinese. Hum Genomics 2011;5:569-76.
14. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathyia B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003;289:579-88.
15. Lee HY, Lee BS, Shin DJ, Park K, Shin YA, Kim KJ, Heo L, Lee JY, Kim YK, Kim YJ, Hong CB, Lee SH, Yoon D, Ku HJ, Oh HY, Kim BJ, Lee J, Park SJ, Kim J, Kawk HK, Lee JE, Park HK, Lee JE, Nam HY, Park HY, Shin C, Yokota M, Asano H, Nakatochi M, Matsubara T, Kitajima H, Yamamoto K, Kim HL, Han BG, Cho MC, Jang Y, Kim HS, Park JE, Lee JY. A genome-wide association study of a coronary artery disease risk variant. J Hum Genet 2013;58:120-6.
Kim DJ, Park M, Cha SH, Kim JW, Han BG, Min H, Ahn Y, Park MS, Han HR, Jang HY, Cho EY, Lee JE, Cho NH, Shin C, Park T, Park JW, Lee JK, Cardon L, Clarke G, McCarthy MI, Lee SY, Lee JK, Oh B, Kim HL. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet 2009;41:527-34.

17. Bierut LJ, Goate AM, Breslau N, Johnson EO, Bertelsen S, Fox L, Agrawal A, Bucholz KK, Grucza R, Hesselbrock V, Kramer J, Kuperman S, Nurnberger J, Poriesz B, Saccone NL, Schuckit M, Tischfield J, Wang JC, Foroud T, Rice JP, Edenberg HJ. ADH1B is associated with alcohol dependence and alcohol consumption in populations of European and African ancestry. Mol Psychiatry 2012;17:445-50.

18. Li H, Borinskaya S, Yoshimura K, Kal’ina N, Marusin A, Stepanov VA, Qin Z, Khaliq S, Lee MY, Yang Y, Mohyuddin A, Gurwitz D, Mehdi SQ, Rogaev E, Jin L, Yankovsky NK, Kidd JR, Kidd KK. Refined geographic distribution of the oriental ALDH2 *504Lys (nee 487Lys) variant. Ann Hum Genet 2009;73:335-45.

19. Takeshita T, Morimoto K. Self-reported alcohol-associated symptoms and drinking behavior in three ALDH2 genotypes among Japanese university students. Alcohol Clin Exp Res 1999;23:1065-9.

20. Nagasawa H, Wada M, Arawaka S, Kawanami T, Kurita K, Daimon M, Adachi M, Hosoya T, Emi M, Muramatsu M, Kato T. A polymorphism of the aldehyde dehydrogenase 2 gene is a risk factor for multiple lacunar infarcts in Japanese men: the Takahata Study. Eur J Neurol 2007;14:428-34.

21. Zee RY, Ridker PM, Cook NR. Prospective evaluation of the alcohol dehydrogenase gamma1/gamma2 gene polymorphism and risk of stroke. Stroke 2004;35:e39-42.

22. Drogan D, Sheldrick AJ, Schütze M, Knüppel S, Andersohn F, di Giuseppe R, Herrmann B, Willich SN, Garbe E, Bergmann MM, Boeing H, Weikert C. Alcohol consumption, genetic variants in alcohol dehydrogenases, and risk of cardiovascular diseases: a prospective study and meta-analysis. PLoS One 2012;7:e32176.

23. Riemann R, Volk R, Müller A, Herzog M. The influence of nocturnal alcohol ingestion on snoring. Eur Arch Otorhinolaryngol 2010;267:1147-56.

24. Koskenvuo M, Kaprio J, Telakivi T, Partinen M, Heikilä K, Sarna S. Snoring as a risk factor for ischaemic heart disease and stroke in men. Br Med J (Clin Res Ed) 1987;294:16-9.

25. Hu FB, Willett WC, Manson JE, Colditz GA, Rimm EB, Speizer FE, Hennekens CH, Stampfer MJ. Snoring and risk of cardiovascular disease in women. J Am Coll Cardiol 2000;35:308-13.

26. Sands M, Loucks EB, Lu B, Carskadon MA, Sharkey K, Stefanick M, Ockene J, Shah N, Hairston KG, Robinson J, Limacher M, Hale L, Eaton CB. Self-reported snoring and risk of cardiovascular disease among postmenopausal women (from the Women’s Health Initiative). Am J Cardiol 2013;111:540-6.

27. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008;321:1493-5.

28. Mackenzie IS, Maki-Petaja KM, McEniery CM, Bao YY, Wallace SM, Cheriyan J, Monteith S, Brown MJ, Wilkinson IB. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol 2005;25:1891-5.

29. Gorelick PB. Alcohol and stroke. Stroke 1987;18:268-71.